Trial Profile
Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms DONATE
- Sponsors AstraZeneca
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.